Law360, New York (June 30, 2010, 3:52 PM ET) -- The U.S. Patent and Trademark Office has denied generic-drug maker Apotex Inc.'s second request for re-examination of the patent for blockbuster blood-thinning drug Plavix, in another boost for partners Bristol-Myers Squibb Co. and Sanofi-Aventis SA in their long-running patent battle with Apotex.
In a decision released June 23, the USPTO said that no substantial new question of patentability affecting the Plavix patent had been raised by Apotex's second request for re-examination, filed April 5.
A spokesman for Apotex could not immediately be reached for comment Wednesday....
USPTO Nixes Apotex Bid for Plavix Patent Re-Exam
To view the full article, take a free trial now.
